Sensei Biotherapeutics, INC Form 4 insider transactions

Principal Financial Officer Josiah Craver of Sensei Biotherapeutics acquired stock options for 50,000 shares on February 14, 2025.

Sensei Biotherapeutics CEO, John Celebi, was granted stock options for 360,000 shares on February 14, 2025, as reported in a Form 4 filing with the SEC.

Edward van der Horst, Chief Scientific Officer of Sensei Biotherapeutics, acquired stock options for 110,000 shares on February 14, 2025.

Stephanie Krebs, Chief Business Officer of Sensei Biotherapeutics, acquired stock options for 120,000 shares on December 20, 2024.

Edward van der Horst, Chief Scientific Officer of Sensei Biotherapeutics, acquired 100,000 stock options on December 20, 2024.

Principal Financial Officer Josiah Craver of Sensei Biotherapeutics acquired 100,000 stock options on December 20, 2024, exercisable at $0.4499, vesting on December 1, 2025.

Sensei Biotherapeutics CEO, John Celebi, was granted stock options to purchase 355,000 shares of common stock.

Cambrian BioPharma Inc., a 10% owner of Sensei Biotherapeutics, Inc., reports acquiring stock options exercisable for 19,000 shares of common stock.

James Peyer, a director of Sensei Biotherapeutics, acquired stock options for 19,000 shares at an exercise price of $0.709 on June 11, 2024.

Director Bob Holmen of Sensei Biotherapeutics acquired 19,000 stock options at an exercise price of $0.709 on June 11, 2024.

Director Jessie English acquired 19,000 stock options in Sensei Biotherapeutics, Inc. on June 11, 2024, at an exercise price of $0.709.

Kristian Humer, a director of Sensei Biotherapeutics, acquired stock options exercisable for 19,000 shares of common stock.

Director William R. Ringo acquired 19,000 stock options in Sensei Biotherapeutics, Inc. on June 11, 2024, at an exercise price of $0.709.

Director Thomas G. Ricks of Sensei Biotherapeutics acquired stock options exercisable for 19,000 shares of common stock.

Director Deneen Vojta acquired 19,000 stock options in Sensei Biotherapeutics, Inc. at an exercise price of $0.709 on June 11, 2024.